Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Mikus

Showing results (41-50 of 194) with videos related to

Pageof 20
Sort By:
Antimicrobial Agents and Chemotherapy|August 31, 2006
Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotypeMarcus J P Geist, Gerlinde Egerer, Jürgen Burhenne, et al.
Addiction Biology|December 24, 2003
P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamineNahal Ketabi-Kiyanvash, Johanna Weiss, Walter Emil Haefeli, et al.
European Journal of Clinical Pharmacology|June 11, 2013
Concentration effect relationship of CYP3A inhibition by ritonavir in humansChristine Eichbaum, Marianna Cortese, Antje Blank, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 13, 2006
Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assayManuela Ehrhardt, Marion Möck, Walter E Haefeli, et al.
British Journal of Clinical Pharmacology|March 3, 2012
Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidineBarbara Grün, Ulrike Merkel, Klaus-Dieter Riedel, et al.
Archives of Toxicology|May 13, 2015
St. John's wort treatment in women bears risks beyond pharmacokinetic drug interactionsNicolas Hohmann, Anna Maus, Alexandra Carls, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 31, 2025
Breaking barriers: The novel in vitro microdialysis system enables reproducing in vivo extraction efficiencies of linezolidFelix Leon Müller, Davide Bindellini, Gerd Mikus, et al.
European Journal of Clinical Pharmacology|October 24, 2018
No alteration of voriconazole concentration by plasmapheresis in a critically ill patientManuela Vay, Kathrin I Foerster, Mazyar Mahmoudi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 15, 2012
Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitroAnja Keubler, Johanna Weiss, Walter E Haefeli, et al.
Journal of Palliative Medicine|January 13, 2018
In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective TrialMarcus J P Geist, Hubert J Bardenheuer, Jürgen Burhenne, et al.
Pageof 20

Showing results (41-50 of 194) with videos related to

Sort By:
Pageof 20
Antimicrobial Agents and Chemotherapy|August 31, 2006
Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotypeMarcus J P Geist, Gerlinde Egerer, Jürgen Burhenne, et al.
Addiction Biology|December 24, 2003
P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamineNahal Ketabi-Kiyanvash, Johanna Weiss, Walter Emil Haefeli, et al.
European Journal of Clinical Pharmacology|June 11, 2013
Concentration effect relationship of CYP3A inhibition by ritonavir in humansChristine Eichbaum, Marianna Cortese, Antje Blank, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 13, 2006
Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assayManuela Ehrhardt, Marion Möck, Walter E Haefeli, et al.
British Journal of Clinical Pharmacology|March 3, 2012
Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidineBarbara Grün, Ulrike Merkel, Klaus-Dieter Riedel, et al.
Archives of Toxicology|May 13, 2015
St. John's wort treatment in women bears risks beyond pharmacokinetic drug interactionsNicolas Hohmann, Anna Maus, Alexandra Carls, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 31, 2025
Breaking barriers: The novel in vitro microdialysis system enables reproducing in vivo extraction efficiencies of linezolidFelix Leon Müller, Davide Bindellini, Gerd Mikus, et al.
European Journal of Clinical Pharmacology|October 24, 2018
No alteration of voriconazole concentration by plasmapheresis in a critically ill patientManuela Vay, Kathrin I Foerster, Mazyar Mahmoudi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 15, 2012
Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitroAnja Keubler, Johanna Weiss, Walter E Haefeli, et al.
Journal of Palliative Medicine|January 13, 2018
In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective TrialMarcus J P Geist, Hubert J Bardenheuer, Jürgen Burhenne, et al.
Pageof 20